PDF
Camurus AB: Change in number of shares and votes in Camurus
Lund - 30 June 2026 - To ensure that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group as resolved by the 2026 Annual General Meeting (Performance Share Plan 2026/2029), Camurus issued 570,000 series C shares to Carnegie Investment Bank AB (publ) in June 2026. All series C shares have been repurchased by Camurus and converted into common shares in accordance with a conversion provision in the articles of association.
As a result of the series C share issue with subsequent repurchase and conversion made under Performance Share Plan 2026/2029, the number of shares and votes has increased by 570,000.
Prior to the issue of series C shares, the total number of shares in Camurus amounted to 59,989,184 corresponding to 59,989,184 votes. As of 30 June 2026, the total number of shares in Camurus amounts to 60,559,184 corresponding to 60,559,184 votes.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7.00 am CET on 30 June 2026.